Our aim is to exploit newly developed device and material technologies to build drug delivery devices for urological indications. We will demonstrate devices to replace intravesical therapies that require frequent instillations of drug solutions into the bladder and also to develop a similar device that can provide localized drug therapy to the seminal vesicle and the prostate gland. Our drug delivery device will have a significant impact on the quality of life for millions of people that suffer from urinary diseases such as overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and superficial bladder cancer. Our approach is to fabricate passive nonresorbable and resorbable release devices that can be deployed and retrieved by conventional cystoscopic procedures. The soluble drugs used for these applications will be stored in the solid form within the device to maximize drug payload and minimize device size. Release of the drug will be controlled by a combination of micro machined orifice and the water permeability of the materials used to construct the device body. Nonresorbable devices will be designed so that they can be retrieved by minimally invasive procedures and constructed from materials that are already used within the bladder. Fully resorbable devices will be fabricated from new elastomeric materials that have been tested for biocompatibility but have not yet been used for urological purposes. In vivo implantation and release experiments of the device will be employed to demonstrate comparable drug exposure to the current intravesical therapies in use for such conditions.

Public Health Relevance

The drug delivery device that is the subject of this research will have a significant impact on the quality of life for millions of people that suffer from urinary diseases such as overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and superficial bladder cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DK081783-01A1
Application #
7661114
Study Section
Urologic and Kidney Development and Genitourinary Diseases Study Section (UKGD)
Program Officer
Kusek, John W
Project Start
2009-09-04
Project End
2011-08-31
Budget Start
2009-09-04
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$223,209
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Tobias, Irene S; Lee, Heejin; Engelmayr Jr, George C et al. (2010) Zero-order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and elastomeric device. J Control Release 146:356-62